Sponsor pipeline

Guliz Ozgun clinical trial pipeline

Get alerts when Guliz Ozgun's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-21

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

  1. Notable

    Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival · Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial

    Primary completion pushed from Dec 2030 to Dec 2031

    Also in this update: Study completion pushed from Dec 2032 to Dec 2033

    Guliz OzgunPhase 3 NCT07338981 Registry history of NCT07338981 on ClinicalTrials.gov (opens the registry)

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 3
2

Disease areas by active trials

Get alerts when Guliz Ozgun's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free